Quanterix Invests In Immunarray, Gains Access To Brain Injury Biomarker Portfolio
Quanterix Corporation, a company digitizing biomarker analysis to accurately measure change for precision health, today announced it is making a strategic investment in ImmunArray, a molecular diagnostics company advancing the development of novel, multi-marker tests for complex diseases with compelling levels of accuracy. As part of the deal, ImmunArray gains access to Quanterix Simoa technology. Both companies are pioneering new approaches to medical diagnoses in complementary areas of neurological disease, focusing on the identification and analysis of molecular biomarkers in the blood.
Read the remainder of the article on GenomeWeb.
Share this page